BioCentury
ARTICLE | Clinical News

CETi-1: Phase I; Phase II

July 21, 2003 7:00 AM UTC

In a dose-ranging, placebo-controlled U.S. Phase I trial in 36 healthy adults, CETi-1 vaccine was well tolerated at 4 different doses. In an extension to the study in 23 patients, 8 of 15 (53%) health...